Search the Newsreel

SCNX Q2'26 Earnings: EPS estimate is (0.09) USD

Scienture Holdings, Inc. (SCNX) is scheduled to announce its Q2'26 earnings on August 17th. Analysts estimate the company will report revenue of 0 USD and an EPS of (0.09) USD for the quarter. This article provides a brief overview of the upcoming earnings report …

Scienture Holdings (SCNX) grows ARBLI revenue but remains loss-making in Q2 2026

Scienture Holdings (SCNX) reported increased revenue in Q2 2026, reaching $343,639, primarily driven by sales of its ARBLI™ (SCN-102) oral suspension. Despite this growth, the company remains loss-making, though its quarterly net loss narrowed significantly to $2.8 million from $6.7 million a year earlier. …

Scienture Holdings: Q2 Earnings Snapshot

The article provides a Q2 earnings snapshot for Scienture Holdings. No financial details or specific performance metrics are available in the provided content. The article is extremely brief, only stating the title and indicating it's an earnings snapshot.

Scienture Begins Nationwide Distribution of 10 mg Opioid-Overdose Spray

Scienture (NASDAQ: SCNX) has commercially launched REZENOPY™ (naloxone hydrochloride) Nasal Spray 10 mg, fulfilling initial U.S. wholesaler purchase orders for its second FDA-approved commercial product. This highest-dose naloxone nasal spray is now being distributed nationwide for emergency treatment of opioid overdose, supported by a …

Scienture Holdings Inc (SCNX) Stock News Today

This article provides an overview of Scienture Holdings Inc. (SCNX) stock information, including its current trading price, market cap, and a note about upcoming news. It indicates that more news regarding the company's stock, earnings, and analyst ratings will be available soon.

Scienture Holdings Inc (SCNX) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for Scienture Holdings Inc (SCNX), indicating a current earnings forecast score of 8.00 and a "Buy" trend based on one analyst's rating with a target price reflecting a 302.47% upside. It details expected revenue for the next quarter …

SCNX|Scienture Holdings Inc|Price:0.355|Chg%:-0.020

This article provides a detailed stock analysis of Scienture Holdings Inc (SCNX), highlighting its healthy fundamentals, significant growth potential, and fair valuation within the Pharmaceuticals industry. The company, focused on developing treatments for central nervous system and cardiovascular diseases, is currently in a growing …

Scienture Holdings Inc (SCNX) Financial Health: Profitability & Balance Sheet Analysis

Scienture Holdings Inc (SCNX) currently holds a financial score of 6.05, placing it 145th out of 155 in the Pharmaceuticals industry, indicating robust financial health but low operating efficiency. The company recently reported a significant year-over-year revenue increase of 449.08% to 56.33K and an …

Scienture Holdings Inc (SCNX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Scienture Holdings Inc (SCNX), detailing its stock price momentum, support and resistance levels, and various technical indicators and moving averages. As of July 29, 2026, SCNX has a price momentum score of 5.32, with the stock trading …

When Will Scienture Holdings, Inc. (NASDAQ:SCNX) Become Profitable?

Scienture Holdings, Inc. (NASDAQ:SCNX) is a pharmaceutical company that has expanded its losses, reporting a US$42m loss recently. Analysts predict the company could reach profitability by 2028, with an expected profit of US$9.0m, requiring an aggressive average annual growth rate of 71%. The company …

Scienture Holdings Inc (SCNX) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Scienture Holdings Inc (SCNX), highlighting its volatility and financial risks. SCNX has a beta value of 3.25, indicating high sensitivity to market movements, and a low risk assessment score within the Pharmaceuticals industry. The report details various …

Scienture Holdings, Inc. Revenue Breakdown – NASDAQ:SCNX

Scienture Holdings, Inc. (NASDAQ:SCNX) generated $431.61K USD in revenue last year, primarily from its Products for the Treatment of Cardiovascular and Central Nervous System Diseases segment. The United States was the leading contributor, accounting for the entire $431.61K USD in revenue, an increase from …

Scienture Holdings Inc (SCNX) Cash Flow

This article provides the quarterly and annual cash flow statements for Scienture Holdings Inc (SCNX), allowing users to assess the company's financial health. It details operating, investing, and financing cash flows, along with related metrics like net income from continuing operations and free cash …

Scienture Holdings Inc (SCNX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides a historical overview of dividend payouts and stock splits for Scienture Holdings Inc (SCNX). It notes that the company has distributed $0.00 in dividends over the past five years and details multiple 15-to-1 merger-related stock splits on June 21, 2023. The …

Scienture Holdings Inc (SCNX) Earnings Date & Reports & Earnings News

SCNX|Scienture Holdings Inc|Price:0.374|Chg%:-0.017

Scienture Holdings Inc. (SCNX) is a specialty pharmaceutical company focused on developing products for central nervous system and cardiovascular diseases. The company is developing several product candidates, including treatments for hypertension, migraine, pain, and thrombosis. Key executives and institutional shareholding information are also provided, …

SCNX SEC Filings - Scienture Holdings, Inc 10-K, 10-Q, 8-K Forms

This page provides a comprehensive resource for investors and traders to access Scienture Holdings (SCNX) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms. It offers direct access to regulatory disclosures, AI-powered summaries, and current market data for SCNX, a Delaware corporation in …

Scienture completes manufacturing for naloxone spray launch By Investing.com

Scienture Holdings Inc. has completed manufacturing of its REZENOPY naloxone hydrochloride nasal spray and will begin shipping to U.S. wholesalers, with commercial availability expected in August. The product, FDA-approved for opioid overdose treatment, taps into a $144 million market, and Scienture, an undervalued healthcare …

$Scienture Holdings (SCNX.US)$

This article consists primarily of navigation links and disclaimers from the moomoo platform, with a single user comment referencing $Scienture Holdings (SCNX.US)$. The user, DaytradeSwing, identifies as a day/swing trader specializing in momentum stocks. The content indicates a user's engagement with the stock within …